Entering text into the input field will update the search result below

Oncolytics Biotech announces a master clinical supply agreement of an anti-PD-L1 checkpoint inhibitor

  • Oncolytics Biotech (NASDAQ:ONCY) has entered into a Master Clinical Supply Agreement (Agreement) with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq) for use in the company’s clinical development program.
  • The supply agreement enables to further investigate pelareorep’s impact on cancer treatments in combination with atezolizumab.
  • Under this five-year Master Clinical Supply Agreement, Roche will supply atezolizumab for the proposed clinical trial with both parties having access to the clinical data.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ONCY
--
ONC:CA
--